
Global Healthy Living Foundation Takes National 340B Reform and Transparency Briefing To New York
'The 340B program is a lifeline when it works as intended — but without oversight, it risks becoming a loophole instead of a safety net.'
Newmark will join lawmakers, academic experts, and fellow advocates to urge greater transparency and accountability in how hospitals and other healthcare institutions use the steep drug discounts they receive under 340B. While originally intended to help vulnerable patients afford essential medications, the program has come under scrutiny for allowing covered entities to pocket savings without passing them along to patients.
'The 340B program is a lifeline when it works as intended — but without oversight, it risks becoming a loophole instead of a safety net,' said Newmark. 'We need reform before expansion. Patients, not institutions, should be the primary beneficiaries.'
As it has in other states, GHLF, a national nonprofit that advocates for people living with chronic illness, is raising concerns about proposed legislation in New York (S.1913 / A.7789) that would make it easier to expand 340B eligibility to additional entities without requiring clear patient benefit or public accountability. The Foundation has issued a memorandum in opposition, warning that such policies may incentivize profit-seeking behavior at the expense of patient care — a trend already observed across multiple states.
The May 13 policy forum, co-hosted by Assemblymember Amanda Septimo and the Community Liver Alliance, comes amid growing national debate about the future of 340B. Lawmakers in Congress have also introduced bills to audit and modernize the program, reflecting a bipartisan understanding that reform is needed to preserve the program's original mission.
Why It Matters Nationally
More than $50 billion in drug discounts flow through 340B each year — yet little data exists on how those savings are used.
Chronic disease patients, especially those with high drug costs, often see no direct community benefit.
Without reform, analysts warn the program may undermine drug pricing systems and continue to erode public trust.
'This isn't just a New York issue. Every state should be asking: is 340B still doing what it was meant to do?' said Newmark.
GHLF urges lawmakers nationwide to adopt transparency mandates, patient benefit requirements, and regular audits before allowing the program to expand further.
About GHLF
The Global Healthy Living Foundation is a U.S. based, 501(c)(3) nonprofit, international organization whose mission is to improve the quality of life for people with chronic illnesses by advocating for improved access to health care through education, patient-centered clinical research, support, advocacy, and economic and policy research. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the international, digital community for millions of people living with arthritis and their supporters worldwide who seek education, support, activism, and patient-centered research in English, Spanish, and French. In addition to arthritis and autoimmune disorders, GHLF supports dermatology, gastroenterology, neurology, cardiology, oncology, infectious disease, rare disease, and pulmonary patients through a host of different programs and activities which draw more than 700,000 patients a month to GHLF websites and create more than 10 million impressions a month on seven social media platforms. In 2024, GHLF had more than 1 million views and listens with its patient-centered audio-visual content, found on YouTube and podcast platforms. GHLF never asks the public for donations, receiving funding instead through governments, non-governmental organizations, foundations, industry, family foundations, and GHLF Co-Founder Louis Tharp. Visit www.ghlf.org for more information.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
14 hours ago
- Business Wire
CareView Communications Launches Partnership with Memorial Hospital Biloxi to Enhance Virtual Sitting Services
LEWISVILLE, Texas--(BUSINESS WIRE)--CareView Communications, Inc., a leading provider of virtual care and patient monitoring solutions ('CareView' or the 'Company') (OTCQB: CRVW), is proud to announce a new partnership with Memorial Hospital Biloxi to improve patient care through advanced virtual sitting technology. This collaboration allows Memorial Hospital Biloxi to leverage CareView's latest state-of-the-art platform. This platform uses predictive technology to enhance care coordination, reduce patient risk, and empower clinical teams to observe patients in real-time from a centralized location. The partnership reflects a shared commitment to delivering high-quality, technology-enabled care to patients across the Gulf Coast region. 'We are excited to partner with Memorial Hospital Biloxi, an organization that shares our passion for patient-centered innovation,' said Sandra McRee, Chief Operating Officer at CareView Communications. 'Together, we will expand access to care, improve clinical outcomes, and support patients by providing enhanced observation and safety through our virtual sitting solution.' CareView's solutions provide real-time visual monitoring, fall-risk alerts, and communication tools that enable staff to intervene quickly and proactively. This information enables Memorial Hospital Biloxi's care teams to reduce adverse events, optimize staffing, and ensure a safer patient environment. Implementing CareView's technology is part of Memorial Hospital Biloxi's broader initiative to invest in digital health solutions that improve operational efficiency while maintaining the highest standards of patient care. For more information about CareView's virtual care solutions, visit About CareView Communications Inc. CareView has been dedicated to supporting hospital care teams for over a decade with its innovative virtual care solutions. The Company has established successful partnerships with over 200 hospitals nationwide, implementing effective inpatient virtual care strategies that greatly enhance patient safety and overcome critical staffing challenges. The CareView platform, fueled by industry-leading predictive technology and supported by its purpose-built hardware, specifically addresses the unique requirements of virtual nursing and virtual sitting use cases. The CareView team works closely with their hospital partners to understand their evolving needs and deliver tailored virtual care strategies that align with their objectives. By providing healthcare professionals with the tools they need to deliver exceptional care, CareView contributes to improved patient outcomes and a more sustainable healthcare ecosystem. Learn more at or follow CareView on LinkedIn. About Memorial Hospital Biloxi Memorial Hospital Biloxi is a not-for-profit, multi-facility healthcare system serving the Mississippi Gulf Coast. With a commitment to excellence, innovation, and community care, Memorial provides a comprehensive range of medical services, including advanced primary and specialty care, across its network of providers and facilities.


Business Wire
16 hours ago
- Business Wire
HCA Healthcare Appoints John W. Chidsey, III as New Independent Director
NASHVILLE, Tenn.--(BUSINESS WIRE)-- HCA Healthcare, Inc. (NYSE: HCA), one of the nation's leading healthcare providers, today announced that its board of directors has appointed John W. Chidsey, III as an independent director, effective July 15, 2025. With his addition, HCA Healthcare's board of directors increases from nine to ten members. Mr. Chidsey will serve as a member of HCA Healthcare's audit and compliance committee, compensation committee and patient safety and quality of care committee. Mr. Chidsey most recently served as the global chief executive officer of Subway. He previously served as chief executive officer of Burger King Holdings, Inc. and held significant leadership roles at Cendant Corporation. Earlier in his career, he also held various senior financial leadership roles at PepsiCo. Mr. Chidsey also currently serves on the board of Norwegian Cruise Line Holdings Ltd. and previously served on the boards of Encompass Health Corporation, Burger King Holdings, Inc. (as chairman) and Brinker International, Inc. 'John Chidsey's distinguished career demonstrates his extensive experience in leading corporate strategy at large, complex public and private companies, and we are confident he will provide invaluable insight as a board member,' said Thomas F. Frist III, chairman of the board of HCA Healthcare. 'John's financial, operational and executive leadership experience and expertise will complement HCA Healthcare's commitment to the care and improvement of human life. We are pleased to announce his addition to our board.' Mr. Chidsey holds a B.A. degree from Davidson College, as well as MBA and J.D. degrees from Emory University. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 192 hospitals and approximately 2,500 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its approximately 44 million annual patient encounters to advance science, improve patient care and save lives. All references to 'Company,' 'HCA' and 'HCA Healthcare' as used throughout this document refer to HCA Healthcare, Inc., and its affiliates.


Business Wire
16 hours ago
- Business Wire
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics
BUSINESS WIRE)-- Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hindered by the use of bacterial cells in the process, which can be unreliable and introduce contamination that must be removed. The second step of GMP-grade RNA production from the template is impeded by a slow, unreliable, and inefficient process in which only one therapy can be made per GMP suite. Consequently, PCT production is slow, very costly, and does not scale for individualized therapies — a new manufacturing paradigm is needed. Nutcracker Therapeutic's NMU-Symphony™ system, the second generation of its Nutcracker® Manufacturing Unit (NMU), brings the fastest, most scalable, and cost-efficient GMP RNA manufacturing platform available today. Fully enclosed and built for speed, it reliably delivers clinical-grade PCTs consistent with just a three-week overall turnaround time, from RNA sequence design to released nanoparticle formulated drug product — cutting traditional timelines in half. By incorporating Elegen's cell-free GMP-ready DNA template production, the combination of the two platforms will enable an even faster and more scalable synthesis of longer, more complex neo-antigen sequences, while eliminating risks of bioburden and endotoxin contamination. With a faster, more reliable and lower-cost solution, Elegen and Nutcracker Therapeutics aim to democratize PCTs, making them accessible to more developers and saving critical time for cancer patients, where even days can make a meaningful impact. 'Integrating cell-free DNA with cell-free biochip-based RNA production gives researchers and partners worldwide access to a more reliable, streamlined, and cost-effective platform to rapidly test and advance new therapies,' said Matthew Hill, founder and CEO of Elegen. 'By eliminating cells from the process, we can accelerate the development and evaluation of new therapeutic modalities, helping patients receive treatment as quickly as possible.' 'We're not just improving our manufacturing process, we're laying the foundation to democratize PCTs with truly scalable solutions,' added Benjamin Eldridge, co-founder and chief technology officer of Nutcracker Therapeutics. 'Achieving that vision means giving developers the ability to produce clinical-grade RNA without investing hundreds of millions in infrastructure. This is a key step toward our mission of delivering scalable, low-cost, and rapid formulated RNA manufacturing for individualized therapies.' Elegen's cell-free ENFINIA DNA with an unparalleled combination of speed, length, accuracy and complexity integrates seamlessly with Nutcracker Therapeutics' existing RNA-based PCT development process, which leverages artificial intelligence and machine learning technologies through its CodonCracker™ RNA design software, the NMU-Symphony™ microfluidics biochip-based system, and ProcessVision™ technology for real-time performance and quality monitoring. Combined, Elegen and Nutcracker Therapeutic's technologies enable the efficient, flexible, and GMP-ready production of individualized nanoparticle-formulated RNA therapeutics. About Elegen, Inc. Elegen brings unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit and connect with us on LinkedIn and X (Twitter). About Nutcracker Therapeutics, Inc. Nutcracker Therapeutics, Inc., is a biotechnology company that combines advanced engineering with high-precision biosynthesis to unlock the promise of RNA for therapeutic developers. The company's mission is to democratize safe and effective RNA-based personalized therapeutics through its complete technology platform, which encompasses the design, delivery, and manufacturing of RNA molecules. Armed with this high-tech advantage, Nutcracker Therapeutics' unique scalable RNA platform significantly reduces costs and cycle times, while maintaining the highest quality. For more information, visit